CANCER: Trials with potential global reach and other challenging trials

Lead Research Organisation: University College London

Abstract

This program includes clinical trials that either present unusual challenges to design and conduct and/or have the potential for global impact (that is, studies of treatments that may more easily applied in even resource-poor countries).
Some of these trials test ‘repurposing’ an approved and marketed drug in an indication distinct from that for which it was licensed, thereby shortening the time needed to make a drug available to patients, and at lower cost.
Another area of focus has to do with the handful of cancer types in which there is a clear association to particular types of infections, such as hepatitis, helicobacter pylori, and human papilloma virus (HPV).
Finally, we use systematic reviews (compiling data from trials already completed anywhere) to identify areas of potential high-impact for new trials, for instance in relation to accuracy of prostate cancer diagnosis.

Technical Summary

This theme relates to trials that either present unusual challenges to design and conduct and/or have the potential for global impact (that is, studies of specific relevance to both resource-poor and resource-rich countries). Challenging trials include those that draw upon this Unit’s specialised experience, such as those requiring extremely large recruitment numbers and/or practical experience managing international collaboration.
One class of trials with global reach involves tests of ‘repurposing’ an approved and marketed drug in an indication distinct from that for which it was licensed. There is currently considerable interest in re-evaluating commonly prescribed medications for their anti-cancer properties.
Repurposing studies have significant potential benefits. Demonstrating efficacy in a new clinical indication for drugs with known toxicity and pharmacokinetics bypasses or shortens some of the steps of the traditional drug evaluation pathway. It also provides access to drugs that are often relatively simple to administer and considerably less expensive than newer agents still within their patent life, and therefore of particular benefit in resource-limited settings. The assessment of aspirin as an adjuvant therapy in several different cancer types within the Add-Aspirin programme is a classic example of such repurposing, as is the ongoing PATCH trial which is evaluating oestradiol patches, designed originally for use in post-menopausal women, as a treatment for prostate cancer.
Systematic review is a key tool for deciding which agents are the best candidates for further evaluation; statins, vitamin D and metformin (an oral hypoglycaemic agent used to treat diabetes), amongst others, are currently being actively investigated for inclusion in either the STAMPEDE and/or the Add-Aspirin trial platforms.
In low resource countries, approximately one quarter of all cancers have been attributed to four chronic infectious causes: helicobacter pylori, hepatitis B and C, and human papilloma virus (HPV). HPV-associated tumours develop mainly in the ano-genital area and oropharynx and all have similar molecular signatures and clinical characteristics. We are actively exploring the feasibility of new platform trials that will bring together researchers with a common interest in HPV-related (or other infection-related) cancers. HPV cancers all contain foreign HPV antigens, which provides an opportunity to exploit immunological based therapies and strategies that have recently led to improved outcomes in other tumour types.
Some cancer trials fit into our portfolio because of particular challenges and their potential impact. Amongst these is the PROMIS study which is testing, in patients with suspected prostate cancer, a diagnostic pathway that includes Multi-Parametric Magnetic Resonance Imaging (MP-MRI). Whilst this is a UK-only study, it is in an extremely common disease setting and has the potential to reduce the substantial over-diagnosis and overtreatment of low grade prostate cancers that carry little risk to survival – a common problem across Western countries. Improving the diagnostic accuracy for prostate cancer, the most common neoplasm in men, would have a huge impact on resource usage, outcomes, and quality of life. Perhaps most importantly, it could provide the basis for a sound approach to prostate cancer screening which has thus far proved a challenge to public health authorities internationally.

Organisations

Publications

10 25 50

publication icon
Blinman PL (2018) Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? in Annals of oncology : official journal of the European Society for Medical Oncology

publication icon
Burdett S (2016) Postoperative radiotherapy for non-small cell lung cancer. in The Cochrane database of systematic reviews

 
Guideline Title NICE Guideline 2: Bladder cancer diagnosis and management
Description Bladder Adj CT IPD (PMID: 16625650) NICE guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 16625650)
 
Guideline Title AUA/ASCO/ASTRO/SUO Guideline treatment of non-metastatic muscle-invasive bladder cancer
Description Bladder Adj CT IPD (PMID:15939530) AUA/ASCO/ASTRO/SUO guideline 2017
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic
Description Bladder Adj CT IPD (PMID:15939530) EAU guideline 2015
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 15939530)
 
Guideline Title Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic
Description Bladder Adj CT IPD (PMID:15939530) EAU guideline 2016
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic
Description Bladder Adj CT IPD (PMID:15939530) EAU guideline 2017
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic
Description Bladder Adj CT IPD (PMID:15939530) EAU guideline 2018
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - v.1.2015 Bladder Cancer
Description Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "Meta-analysis suggests a survival benefit to adjuvant therapy for pathologic T3, T4 or N+ disease at cystectomy"...."A meta-analysis of 6 trials found a 25% mortality reduction with adjuvant chemotherapy, but the authors pointed out several limitations of the data and concluded that evidence is insufficient for treatment", based on our systematic review and meta-analysis of IPD (PMID: 15939530)
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - v.1.2017 Bladder Cancer
Description Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - v.1.2018 Bladder Cancer
Description Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - v.1.2019 Bladder Cancer
Description Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2019
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic
Description Bladder Neo CT IPD (PMID: 12801735; 15939524) EAU guideline 2015
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
Impact "Neoadjuvant cisplatin-containing combination chemotherapy improves OS (5-8% at 5 years)", based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524)
 
Guideline Title SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
Description Bladder Neo CT IPD (PMID: 12801735; 15939524) SEOM guideline 2018
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial urinary bladder cancer
Description Bladder Neo CT IPD (PMID: 12801735; 15939524) SOS/SUA guideline 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic
Description Bladder Neo CT IPD (PMID: 15939524) EAU guideline 2016
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic
Description Bladder Neo CT IPD (PMID: 15939524) EAU guideline 2017
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 1.2015
Description Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact In a meta-analysis of 11 trials involving 3,005 patients, platinum-based neoadjuvant chemotherapy was associated with improved 5-year overall and disease-free survival (5% and 9% absolute improvement, respectively), based on our systematic review and meta-analysis of IPD (PMID: 15939524)
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 1.2017
Description Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 1.2018
Description Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 1.2019
Description Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2019
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title SEOM clinical guidelines for the treatment of invasive bladder cancer (2016)
Description Bladder Neo CT IPD (PMID: 15939524, PMID: 12801735) SEOM guideline 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NICE Guideline 2: Bladder cancer diagnosis and management
Description Bladder Neo CT IPD (PMID:15846746) NICE guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "One systematic review and meta-analysis of individual patient data (3,005 patients from 11 randomised trials) was identified (Advanced Bladder Cancer Meta-Analysis Collaboration (ABC), 2004). No other randomised trials were identified. High quality evidence about overall survival came from 10 trials with a total of 2,809 patients".....Recommendation: "Offer neoadjuvant chemotherapy using a cisplatin combination regimen before radical cystectomy or radical radiotherapy to people with newly diagnosed muscle-invasive urothelial bladder cancer for whom cisplatin-based chemotherapy is suitable. Ensure that they have an opportunity to discuss the risks and benefits with an oncologist who treats bladder cancer.", based on our systematic review and meta-analysis of IPD (PMID:15846746)
 
Guideline Title UK guidelines for the management of bone sarcomas
Description British Sarcoma Group: UK guidelines for the management of bone sarcomas (in BMC Clinical Sarcoma Research)
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
Impact Not known
URL https://clinicalsarcomaresearch.biomedcentral.com/articles/10.1186/s13569-016-0047-1
 
Guideline Title Cancer of the Uterine Cervix
Description Cervix CTRT IPD (PMID:19001332) AHS guideline 2015
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact "Medically fit patients with advanced stage cervical cancer (stage IB2/IIB/IIIA/IIIB/IVA), as well as select stage IIA cases, should be considered for treatment with concurrent radiotherapy and chemotherapy.8,10,13,18 A meta-analysis of 13 trials showed that chemoradiotherapy (versus radiotherapy alone) increased the disease free survival rate at five years by eight percent.17 There was a significant trend towards increased overall survival with decreasing stage of disease (p = 0.017), with stage IA/IB/IIA patients achieving the lowest hazard ratio for death.", based on our systematic review and meta-analysis of IPD (PMID: 19001332)
 
Guideline Title NCCN Practice Guidelines in Oncology - v.2.2015 Cervical Cancer
Description Cervix CTRT IPD (PMID:19001332) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "A recent meta-analysis reported that chemoradiotherapy leads to a 6% improvement in 5-year survival (hazard ratio, 0.81; P <.001)", based on our systematic review and meta-analysis of IPD (PMID: 19001332)
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2016 Cervical Cancer
Description Cervix CTRT IPD (PMID:19001332) NCCN guideline 2016
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "A recent meta-analysis reported that chemoradiotherapy leads to a 6% improvement in 5-year survival (hazard ratio, 0.81; P <.001)", based on our systematic review and meta-analysis of IPD (PMID: 19001332)
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2017 Cervical Cancer
Description Cervix CTRT IPD (PMID:19001332) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2018 Cervical Cancer
Description Cervix CTRT IPD (PMID:19001332) NCCN guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.3.2019 Cervical Cancer
Description Cervix CTRT IPD (PMID:19001332) NCCN guideline 2019
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Cervix CTRT IPD (PMID:19001332) SEOM guideline 2015
Description Cervix CTRT IPD (PMID:19001332) SEOM guideline 2015
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
Impact "Primary cisplatin-based chemo-radiotherapy is the treatment of choice in locally advanced cervical cancer (Level of evidence Ia; Recommendation level A)." For stages IB2, IIA2, IIB-IVA), based on our systematic review and meta-analysis of IPD (PMID: 19001332)
 
Guideline Title SEOM clinical guidelines for cervical cancer 2015
Description Cervix Neo CT IPD (PMID: 14602133) SEOM guideline 2015
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
Impact "To date, neoadjuvant chemotherapy before either standard concurrent chemo-radiation or radical surgery is not a standard approach (Level of evidence IIa; Category of recommendation C).", based on our systematic review and meta-analysis of IPD (PMID: 14602133)
 
Guideline Title Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Description Cervix Neo CT IPD (PMID: 14602133)(PMID: 15106161) ESMO guideline 2017
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline
Description Cervix Neo CT IPD (PMID: 15106161) ASCO guideline 2016
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Description Cervix Neo CT IPD (PMID: 19001332) ESMO guideline 2017
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.2.2015 Cervical Cancer
Description Cervix Neo CT SR (PMID:20091632) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "Although neoadjuvant chemotherapy followed by surgery has been used in areas where RT is not available, data suggest no improvement in survival when compared with surgery alone for early-stage cervical cancer", based on our systematic review and meta-analysis of summary data (PMID: 20091632)
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2016 Cervical Cancer
Description Cervix Neo CT SR (PMID:20091632) NCCN guideline 2016
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "Although neoadjuvant chemotherapy followed by surgery has been used in areas where RT is not available, data suggest no improvement in survival when compared with surgery alone for early-stage cervical cancer", based on our systematic review and meta-analysis of summary data (PMID: 20091632)
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2017 Cervical Cancer
Description Cervix Neo CT SR (PMID:20091632) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.1.2018 Cervical Cancer
Description Cervix Neo CT SR (PMID:20091632) NCCN guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.3.2019 Cervical Cancer
Description Cervix Neo CT SR (PMID:20091632) NCCN guideline 2019
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Cancer of the Uterine Cervix
Description Cervix Neo CT SR (PMID:23235641) AHS guideline 2015
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 23235641)
 
Guideline Title Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline
Description Cervix Neo CT SR (PMID:23235641) AHS guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Description Cervix Neo CT SR (PMID:23235641) ESMO guideline 2017
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title BMJ Best Practice -- Osteosarcoma: The right clinical information, right where it's needed
Description Cited in clinical guidelines -- BMJ Best Practice (Feb-2019)
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
URL https://bestpractice.bmj.com/topics/en-gb/780/pdf/780.pdf
 
Guideline Title ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up (2018)
Description Cited in clinical guidelines -- ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up (2018)
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
URL https://academic.oup.com/annonc/article/29/Supplement_4/iv79/5115250
 
Guideline Title Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
Description Colorectal Anti-EGFR SR (PMID:22118887) ASCO guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Guidelines Version 2.2015 Colon Cancer
Description Colorectal Anti-EGFR SR (PMID:22118887) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "A recent meta-analysis concluded there was a clear benefit to the use of EGFR inhibitors in patients with KRAS-wild-type metastatic colorectal cancer", based on our systematic review and meta-analysis of summary data (PMID: 22118887)
 
Guideline Title S3-Leitlinie diagnostik, therapie und nachsorge der patientinnen mit endometrriumkarzinom
Description Endometrial CT SR (PMID: 22895938) GGPO guideline 2017
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title S3-Leitlinie diagnostik, therapie und nachsorge der patientinnen mit endometrriumkarzinom
Description Endometrial CT SR (PMID: 22895938) GGPO guideline 2018
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Endometrial cancer clinical practice guideline GYNE-002
Description Endometrial CT SR (PMID:17150999) AHS guideline 2015
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact "..a meta-analysis by Humber, et al.in 2007 concluded that combination chemotherapy was superior to single agent chemotherapy, with the addition of anthracyclines and taxanes to cisplatin giving the best response.", based on our systematic review and meta-analysis of summary data (PMID: 17150999)
 
Guideline Title NCCN Practice Guidelines in Oncology v.2.2015. Uterine Neoplasms
Description Endometrial CT SR (PMID:17150999) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "Based on the current data, multiagent chemotherapy regimens are preferred for metastatic, recurrent, or high-risk disease, if tolerated", based on our systematic review and meta-analysis of summary data (PMID: 17150999)
 
Guideline Title NCCN Practice Guidelines in Oncology v.2.2016. Uterine Neoplasms
Description Endometrial CT SR (PMID:17150999) NCCN guideline 2016
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "Based on the current data, multiagent chemotherapy regimens are preferred for metastatic, recurrent, or high-risk disease, if tolerated", based on our systematic review and meta-analysis of summary data (PMID: 17150999)
 
Guideline Title NCCN Practice Guidelines in Oncology v.2.2017. Uterine Neoplasms
Description Endometrial CT SR (PMID:17150999) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.1 2018. Uterine Neoplasms
Description Endometrial CT SR (PMID:17150999) NCCN guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.3 2019. Uterine Neoplasms
Description Endometrial CT SR (PMID:17150999) NCCN guideline 2019
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - v.1.2015 Central Nervous System Cancers
Description Glioma CT IPD (PMID:11937180) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "In contrast, 2 meta-analyses reviewed data from randomized trials of high-grade glioma patients, and both found a modest survival benefit when chemotherapy was added to postoperative RT. Specifically, the Glioma Meta- Analysis Trialists Group reviewed 12 studies involving approximately 3000 patients and reported an absolute increase in 1-year survival from 40% to 46% and a 2-month increase in median survival when chemotherapy was added to postoperative RT (HR, 0.85; 95% CI, 0.78- 0.91; P < .0001)", based on our systematic review and meta-analysis of IPD (PMID:11937180)
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - v.1.2017 Central Nervous System Cancers
Description Glioma CT IPD (PMID:11937180) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology - v.1.2017 Central Nervous System Cancers
Description Glioma CT IPD (PMID:11937180) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC?
Description Lung Adj CT IPD (PMID: 20338628) CCA guideline stage III Adj CT operable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC?
Description Lung Adj CT IPD (PMID: 20338628) CCA guideline stage III Adj CT operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?
Description Lung Adj CT IPD (PMID: 20338628) CCA guideline stage III NeoAdj CT operable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?
Description Lung Adj CT IPD (PMID: 20338628) CCA guideline stage III NeoAdj CT operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: An American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline
Description Lung Adj CT IPD (PMID:20338628) ASTRO guideline Def Adj RT 2015
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact "Currently, adjuvant CT has become the standard of care for patients with completely resected stage II and III NSCLC, after the results from multiple randomized trials, later validated by meta-analyses,demonstrated that addition of platinum-based CT after resection of LA NSCLC leads to absolute overall survival improvements at 5 years of between 5% and 15%", based on our systematic review and meta-analysis of IPD (PMID: 20338628)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?
Description Lung Adj CT IPD (PMID:20338628) CCA guideline stage II CT after operable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of postoperative radiotherapy (PORT) in the treatment of resected stage III NSCLC?
Description Lung Adj CT IPD (PMID:20338628) CCA guideline stage III PORT resected 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of postoperative radiotherapy (PORT) in the treatment of resected stage III NSCLC?
Description Lung Adj CT IPD (PMID:20338628) CCA guideline stage III PORT resected 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Postoperative adjuvant systemic therapy in completely resected non-small cell lung cancer. Guideline 7-1-2 Version 2
Description Lung Adj CT IPD (PMID:20338628) CCO guideline post-op tx after operable 2016
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact "Key Evidence for recommendation 1"..... "An individual patient analysis of 26 randomized controlled trials (RCTs) demonstrated a significant survival benefit in patients receiving adjuvant chemotherapy compared with the observation group (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.81 to 0.92; p<0.0001) representing an absolute improvement of 4% (95% CI, 3 to 6) at five years.", based on our systematic review and meta-analysis of IPD (PMID: 20338628)
 
Guideline Title Early-Stage and Locally Advanced (non-metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines
Description Lung Adj CT IPD (PMID:20338628) ESMO guideline 2017
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer
Description Lung Adj CT IPD (PMID:20338628) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "The NCCN Panel recommends chemotherapy (category 1) for patients with negative surgical margins and stage II disease, including 1) T1ab- 2a, N1; 2) T2b, N1; or 3) T3, N0 disease", based on our systematic review and meta-analysis of IPD (PMID: 20338628)
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer
Description Lung Adj CT IPD (PMID:20338628) NCCN guideline 2016
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "The NCCN Panel recommends chemotherapy (category 1) for patients with negative surgical margins and stage II disease, including 1) T1ab- 2a, N1; 2) T2b, N1; or 3) T3, N0 disease"..."Postoperative adjuvant sequential chemotherapy with RT is recommended for patients with T1-3, N2 disease and negative margins . A meta-analysis assessed postoperative chemotherapy with (or without) postoperative RT in patients mainly with stage III disease.675 In this meta-analysis, 70% of the eligible trials used adjuvant chemotherapy before RT; 30% used concurrent chemo/RT. Regimens included cisplatin/vinorelbine followed by RT or concurrent cisplatin/etoposide.", based on our systematic review and meta-analysis of IPD (PMID: 20338628)
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer
Description Lung Adj CT IPD (PMID:20338628) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.3.2019. Non-Small Cell Lung Cancer
Description Lung Adj CT IPD (PMID:20338628) NCCN guideline 2019
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Description Lung Adj CT IPD (PMID:20338628, 25730344) SEOM guideline 2018
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: ASCO Clinical Practice Guideline Update
Description Lung Adj CT IPD (PMID:25730344) ASCO guideline 2017
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Lung Adj CT IPD (PMID:25730344)(PMID: 20338628) CCA guideline stage II CT after operable 2016
Description Lung Adj CT IPD (PMID:25730344)(PMID: 20338628) CCA guideline stage II CT after operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title ASCO Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small Cell Lung Cancer
Description Lung CT 95 IPD (PMID:7580546) ASCO guideline stage I-III NSCLC 2017
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: An American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline
Description Lung CT 95 IPD (PMID:7580546) ASTRO guideline Def Adj RT 2015
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?
Description Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT after operable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?
Description Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT after operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?
Description Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT before operable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?
Description Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT before operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC?
Description Lung CT 95 IPD (PMID:7580546) CCA guideline stage III Adj CT operable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC?
Description Lung CT 95 IPD (PMID:7580546) CCA guideline stage III Adj CT operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease?
Description Lung CT 95 IPD (PMID:7580546) CCA guideline stage III GoodPS inoperable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact "In good performance status patients with inoperable stage III NSCLC, the addition of chemotherapy to radiation therapy is associated with a statistically significant survival benefit compared with radiation therapy alone", based on our systematic review and meta-analysis of IPD (PMID: 7580546)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease?
Description Lung CT 95 IPD (PMID:7580546) CCA guideline stage III GoodPS inoperable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?
Description Lung CT 95 IPD (PMID:7580546) CCA guideline stage IV 1stLineCT inoperable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact "Platinum-based chemotherapy improves survival in stage IV NSCLC compared with best supportive care. Note that this evidence is based on clinical trials conducted in fit patients, with predominant performance status 0-1, no unstable co-morbidities, adequate organ function and without uncontrolled brain metastases.", based on our systematic review and meta-analysis of IPD (PMID: 7580546)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?
Description Lung CT 95 IPD (PMID:7580546) CCA guideline stage IV 1stLineCT inoperable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Evidence-based recommendations for the management of non-small cell lung cancer (NSCLC)
Description Lung CT 95 IPD (PMID:7580546) CCMB guideline 2015
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact "There is level I evidence for patients to receive platinum-based post-surgical adjuvant chemotherapy in II and IIIA NSCLC", based on our systematic review and meta-analysis of IPD (PMID: 7580546)
 
Guideline Title Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines
Description Lung CT 95 IPD (PMID:7580546) ESMO guideline stage M1 NSCLC 2016
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines
Description Lung CT 95 IPD (PMID:7580546) ESMO guideline stage M1 NSCLC 2016
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2017
Description Lung CT 95 IPD (PMID:7580546) GGPO guideline 2017
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2018
Description Lung CT 95 IPD (PMID:7580546) GGPO guideline 2018
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer
Description Lung CT 95 IPD (PMID:7580546) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial", based on our systematic review and meta-analysis of IPD (PMID: 7580546)
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer
Description Lung CT 95 IPD (PMID:7580546) NCCN guideline 2016
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial", based on our systematic review and meta-analysis of IPD (PMID: 7580546)
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer
Description Lung CT 95 IPD (PMID:7580546) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.2.2018. Non-Small Cell Lung Cancer
Description Lung CT 95 IPD (PMID:7580546) NCCN guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.3.2019. Non-Small Cell Lung Cancer
Description Lung CT 95 IPD (PMID:7580546) NCCN guideline 2019
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?
Description Lung Neo CT IPD (PMID: 24576776) CCA guideline stage III NeoAdj CT operable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact "In patients with clinical stage IIIA disease treated by surgery, neoadjuvant chemotherapy reduces the relative risk of death by 13%, and improves absolute 5 year survival rates from 20 to 25%"; "It is recommended to consider pre-operative administration of 2-3 cycles of platinum doublet-based, third-generation chemotherapy as a treatment option in good performance status patients with operable clinical stage IIIA non-small cell lung cancer.", based on our systematic review and meta-analysis of IPD (PMID: 24576776)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?
Description Lung Neo CT IPD (PMID: 24576776) CCA guideline stage III NeoAdj CT operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Early-Stage and Locally Advanced (non-metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines
Description Lung Neo CT IPD (PMID: 24576776) ESMO guideline 2017
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2018
Description Lung Neo CT IPD (PMID: 24576776) GGPO guideline 2018
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2017
Description Lung Neo CT IPD (PMID: 24576776) GGPO guideline 2018
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer
Description Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "The NCCN Guidelines state that patients with stage II or IIIA (T3, N1) disease may be treated with induction chemotherapy before surgery if they are candidates for adjuvant therapy after surgery", based on our systematic review and meta-analysis of IPD (PMID: 24576776)
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer
Description Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2016
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "The NCCN Guidelines state that patients with stage II or IIIA (T3, N1) disease may be treated with induction chemotherapy before surgery if they are candidates for adjuvant therapy after surgery", based on our systematic review and meta-analysis of IPD (PMID: 24576776)
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer
Description Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.2.2018. Non-Small Cell Lung Cancer
Description Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.3.2019. Non-Small Cell Lung Cancer
Description Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2019
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC?
Description Lung Neo CT SR (PMID: 17636828) CCA guideline stage III Adj CT operable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17636828)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC?
Description Lung Neo CT SR (PMID: 17636828) CCA guideline stage III Adj CT operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?
Description Lung Neo CT SR (PMID: 17636828) CCA guideline stage III NeoAdj CT operable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17636828)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?
Description Lung Neo CT SR (PMID: 17636828) CCA guideline stage III NeoAdj CT operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
Description Lung Neo CT SR (PMID: 17636828) SEOM guideline 2015
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
Impact "The Cochrane meta-analysis demonstrated that preoperative therapy is better than surgery alone for patients with stage III", based on our systematic review and meta-analysis of summary data (PMID: 17636828)
 
Guideline Title SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Description Lung Neo CT SR (PMID: 17636828) SEOM guideline 2018
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage I NSCLC?
Description Lung Neo CT SR (PMID:17409927) CCA guideline stage I CT before operable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage I NSCLC?
Description Lung Neo CT SR (PMID:17409927) CCA guideline stage I CT before operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?
Description Lung Neo CT SR (PMID:17409927) CCA guideline stage II CT before operable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?
Description Lung Neo CT SR (PMID:17409927) CCA guideline stage II CT before operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?
Description Lung Neo CT SR (PMID:24576776) CCA guideline stage II CT before operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2017
Description Lung PORT IPD (PMID: 9690404) GGPO guideline 2017
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2018
Description Lung PORT IPD (PMID: 9690404) GGPO guideline 2018
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer
Description Lung PORT IPD (PMID: 9690404) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404)
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer
Description Lung PORT IPD (PMID: 9690404) NCCN guideline 2016
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "PORT is not recommended for patients with pathologic stage N0-1 disease, because it has been associated with increased mortality, at least when using older RT techniques" , based on our systematic review and meta-analysis of IPD (PMID: 9690404)
 
Guideline Title NCCN Practice Guidelines in Oncology v.2.2018. Non-Small Cell Lung Cancer
Description Lung PORT IPD (PMID: 9690404) NCCN guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.3.2019. Non-Small Cell Lung Cancer
Description Lung PORT IPD (PMID: 9690404) NCCN guideline 2019
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer
Description Lung PORT IPD (PMID: 9690404; 15603857) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Evidence-based recommendations for the management of non-small cell lung cancer (NSCLC)
Description Lung PORT IPD (PMID: 9690404; 15846628) CCMB guideline 2015
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact "Post-operative radiation therapy is not recommended as a standard of practice following complete resection of stage I and II NSCLC", based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15846628)
 
Guideline Title Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: An American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline
Description Lung PORT IPD (PMID: 9690404; 15846628; 15603857) ASTRO guideline Def Adj RT 2015
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact "Phase III studies and meta-analyses of PORT in completely resected (R0) LA NSCLC with N0-1 disease demonstrate inferior survival when compared to observation strategies; therefore, PORT therapy for this patient population is not routinely recommended.", based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15846628; PMID: 15603857)
 
Guideline Title Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: ASCO Clinical Practice Guideline Update
Description Lung PORT IPD (PMID: 9690404; 23453644) ASCO guideline 2017
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of radiotherapy after surgery in the treatment of operable stage I NSCLC?
Description Lung PORT IPD (PMID:15846628) CCA guideline stage I RT after operable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact "There is strong evidence, based on an individual patient data meta-analysis and recently updated, that the use of postoperative radiotherapy following complete resection of stage I NSCLC is detrimental, and is associated with worse survival. In patients who have had complete resection of stage I NSCLC, postoperative radiotherapy is not recommended", based on our systematic review and meta-analysis of IPD (PMID: 15846628)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer: What is the role of radiotherapy after surgery in the treatment of operable stage I NSCLC?
Description Lung PORT IPD (PMID:15846628) CCA guideline stage I RT after operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of radiotherapy after surgery in the treatment of operable stage II NSCLC?
Description Lung PORT IPD (PMID:15846628) CCA guideline stage II RT after operable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact "In patients who have had complete resection of stage II NSCLC, postoperative radiotherapy is not recommended", based on our systematic review and meta-analysis of IPD (PMID: 15846628)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of radiotherapy after surgery in the treatment of operable stage II NSCLC?
Description Lung PORT IPD (PMID:15846628) CCA guideline stage II RT after operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of postoperative radiotherapy (PORT) in the treatment of resected stage III NSCLC?
Description Lung PORT IPD (PMID:15846628) CCA guideline stage III PORT resected 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact "A meta-analysis demonstrates no clear evidence of an adverse or beneficial effect of PORT on survival in patients with pN2 disease", based on our systematic review and meta-analysis of IPD (PMID: 15846628)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of postoperative radiotherapy (PORT) in the treatment of resected stage III NSCLC?
Description Lung PORT IPD (PMID:15846628) CCA guideline stage III PORT resected 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Early-Stage and Locally Advanced (non-metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines
Description Lung PORT IPD (PMID:15846628) ESMO guideline 2017
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
Description Lung PORT IPD (PMID:15846628) SEOM guideline 2015
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
Impact "PORT is not recommended for patients with completely resected stage I-II NSCLC (IA and IIA, respectively)", based on our systematic review and meta-analysis of IPD (PMID: 15846628)
 
Guideline Title Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2017
Description Lung SC IPD (PMID: 18678835) GGPO guideline 2017
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2018
Description Lung SC IPD (PMID: 18678835) GGPO guideline 2018
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer
Description Lung SC IPD (PMID: 18678835) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial", based on our systematic review and meta-analysis of IPD (PMID: 18678835)
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer
Description Lung SC IPD (PMID: 18678835) NCCN guideline 2016
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial", based on our systematic review and meta-analysis of IPD (PMID: 18678835)
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer
Description Lung SC IPD (PMID: 18678835) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.2.2018. Non-Small Cell Lung Cancer
Description Lung SC IPD (PMID: 18678835) NCCN guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.3.2019. Non-Small Cell Lung Cancer
Description Lung SC IPD (PMID: 18678835) NCCN guideline 2019
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Description Lung SC IPD (PMID: 18678835) SEOM guideline 2018
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update
Description Lung SC IPD (PMID: 20464750) ASCO guideline systemic Stage IV 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "Cochrane systematic review on chemotherapy and supportive care... continued to show that chemotherapy and best supportive care versus supportive care alone benefit patients, including those who have PS 2", based on our systematic review and meta-analysis of IPD (PMID: 20464750)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?
Description Lung SC IPD (PMID: 20464750) CCA guideline stage II CT after operable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20464750)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?
Description Lung SC IPD (PMID: 20464750) CCA guideline stage II CT after operable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?
Description Lung SC IPD (PMID: 20464750) CCA guideline stage IV 1stLineCT inoperable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact "Platinum-based chemotherapy improves survival in stage IV NSCLC compared with best supportive care. Note that this evidence is based on clinical trials conducted in fit patients, with predominant performance status 0-1, no unstable co-morbidities, adequate organ function and without uncontrolled brain metastases.", based on our systematic review and meta-analysis of IPD (PMID: 20464750)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?
Description Lung SC IPD (PMID: 20464750) CCA guideline stage IV 1stLineCT inoperable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy when added to radiotherapy in the treatment of inoperable stage II NSCLC?
Description Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage II CTRT inoperable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20351327)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy when added to radiotherapy in the treatment of inoperable stage II NSCLC?
Description Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage II CTRT inoperable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease?
Description Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage III GoodPS inoperable 2015
Geographic Reach Australia 
Policy Influence Type Citation in clinical guidelines
Impact "For patients with good performance status and inoperable stage III NSCLC, the concurrent administration of chemotherapy and radiotherapy is recommended.", based on our systematic review and meta-analysis of IPD (PMID: 20351327)
 
Guideline Title Clinical practice guidelines for the treatment of lung cancer. What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease?
Description Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage III GoodPS inoperable 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Early-Stage and Locally Advanced (non-metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines
Description Lung SeqCon CTRT IPD (PMID:20351327) ESMO guideline 2017
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2017
Description Lung SeqCon CTRT IPD (PMID:20351327) GGPO guideline 2017
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2018
Description Lung SeqCon CTRT IPD (PMID:20351327) GGPO guideline 2018
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer
Description Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "Concurrent chemoradiation is superior to sequential therapy for patients with unresectable stage III disease" "When distant metastases are not present, the NCCN Panel recommends that the patient be treated with definitive concurrent chemoradiation therapy" , based on our systematic review and meta-analysis of IPD (PMID: 20351327)
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer
Description Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2016
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "The standard of care for patients with inoperable stage II (node positive) and stage III is concurrent chemotherapy/RT" "Concurrent chemoradiation is superior to sequential therapy for patients with unresectable stage III disease." "When distant metastases are not present, the NCCN Panel recommends that the patient be treated with definitive concurrent chemoradiation therapy" , based on our systematic review and meta-analysis of IPD (PMID: 20351327)
 
Guideline Title NCCN Practice Guidelines in Oncology v.2.2018. Non-Small Cell Lung Cancer
Description Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer
Description Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology v.3.2019. Non-Small Cell Lung Cancer
Description Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2019
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
Description Lung SeqCon CTRT IPD (PMID:20351327) SEOM guideline 2015
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20351327)
 
Description Membership of Aspirin Foundation Scientific Advisory Board
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
URL http://www.aspirin-foundation.com/scientific-advisory-board/
 
Description Membership of Psycho-social oncology and survivorship NCRI CSG
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) Hodgkin Lymphoma Version 1.2018 - December 20, 2017
Description NCCN guideline 2017 - Hodgkin lymphoma - LY09
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
URL https://www.nccn.org/professionals/physician_gls/pdf/hodgkin_blocks.pdf
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology -- Prostate Cancer (v1.2019 -- 06-Mar-2019)
Description NCCN guidelines (updated Mar-2019) - PR07 (4 papers)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
URL https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology -- Prostate Cancer (v1.2019 -- 06-Mar-2019)
Description NCCN guidelines (updated Mar-2019) - RT01 (1 paper)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
URL https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
 
Guideline Title NICE guidance 2018 for management of brain tumours
Description NICE guidance 2018 for management of brain tumours
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact The MRC/CRUK/EORTC trial established the improvement in survival at 5 years related to the use of chemotherapy
URL https://www.nice.org.uk/guidance/ng99/chapter/Recommendations#management-of-glioma
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology Bone Cancer
Description National Comprehensive Cancer Network - EURAMOS-1 Good Responders
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact Not known
URL https://emedicine.medscape.com/article/1256857-guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology Bone Cancer
Description National Comprehensive Cancer Network - EURAMOS-1 Poor Responders
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
URL https://emedicine.medscape.com/article/1256857-guidelines
 
Guideline Title Leitlinienprogramm onkologie. Diagnostik und therapie des Ösophaguskarzinoms v1.0 2015
Description Oesophagus RT IPD (PMID:16235286) GGPO guideline 2015
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
Impact "Eine alleinige präoperative Strahlentherapie kann beim operablen Patienten mit einem resektablen Ösophaguskarzinom nicht empfohlen werden.", based on our systematic review and meta-analysis of IPD (PMID: 16235286)
 
Guideline Title Leitlinienprogramm onkologie. Diagnostik und therapie des Ösophaguskarzinoms v2.0 2018
Description Oesophagus RT IPD (PMID:16235286) GGPO guideline 2018
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Evidence-based recommendations for the management of potentially curable esophageal carcinoma
Description Oesophagus RT IPD (PMID:9635705) CCMB guideline 2015
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 9635705)
 
Guideline Title NCCN Guidelines Version 3.2015 Esophageal and Esophagogastric Junction Cancers
Description Oesophagus RT IPD (PMID:9635705) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "A meta-analysis from the Oesophageal Cancer Collaborative Group also showed no clear evidence of a survival advantage with preoperative radiation", based on our systematic review and meta-analysis of IPD. (PMID: 9635705)
 
Guideline Title NCCN Guidelines Version 3.2016 Esophageal and Esophagogastric Junction Cancers
Description Oesophagus RT IPD (PMID:9635705) NCCN guideline 2016
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Guidelines Version 4.2017 Esophageal and Esophagogastric Junction Cancers
Description Oesophagus RT IPD (PMID:9635705) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Guidelines Version 2.2018 Esophageal and Esophagogastric Junction Cancers
Description Oesophagus RT IPD (PMID:9635705) NCCN guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Description Prostate ABI SR (PMID: 28800492) ASCO guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU-ESTRO-ESUR-SIOG GUIDELINES ON PROSTATE CANCER
Description Prostate ABI SR (PMID: 28800492) EAU guideline 2018
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Description Prostate CT SR (PMID: 26718929) ASCO guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU-ESTRO-ESUR-SIOG Guidelines on prostate cancer
Description Prostate CT SR (PMID: 26718929) EAU guideline 2017
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title EAU-ESTRO-ESUR-SIOG GUIDELINES ON PROSTATE CANCER
Description Prostate CT SR (PMID: 26718929) EAU guideline 2018
Geographic Reach Europe 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der ver-schiedenen Stadien des Prostatakarzinoms
Description Prostate CT SR (PMID: 26718929) GGPO guideline 2017
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title JUA Evidence-based clinical practice guideline for prostate cancer
Description Prostate CT SR (PMID: 26718929) JUA guideline 2017
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Practice Guidelines in Oncology - v.4.2018 Prostate Cancer
Description Prostate CT SR (PMID: 26718929) NCCN guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title SEOM clinical guidelines for the treatment of metastatic prostate
Description Prostate CT SR (PMID: 26718929) SEOM guideline 2017
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.1.2015 Soft Tissue Sarcoma
Description Sarcoma CT IPD (PMID:9400508) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "The Sarcoma Meta Analysis Collaboration (SMAC) performed a meta-analysis of 14 randomized trials (1,568 patients) which compared adjuvant chemotherapy to follow-up and in some cases RT after surgery with a variety of sarcomas. The result of the meta-analysis showed that doxorubicin-based chemotherapy prolongs local and distant recurrence and overall RFS in adults with localized, resectable STS of the extremity and was associated with decreased recurrence rates. The OS advantage was not significant, although there was a trend in favor of postoperative chemotherapy", based on our systematic review and meta-analysis of IPD (PMID: 9400508)
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.1.2016 Soft Tissue Sarcoma
Description Sarcoma CT IPD (PMID:9400508) NCCN guideline 2016
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact "The Sarcoma Meta Analysis Collaboration (SMAC) performed a meta-analysis of 14 randomized trials (1,568 patients) which compared adjuvant chemotherapy to follow-up and in some cases RT after surgery with a variety of sarcomas. The result of the meta-analysis showed that doxorubicin-based chemotherapy prolongs local and distant recurrence and overall RFS in adults with localized, resectable STS of the extremity and was associated with decreased recurrence rates. The OS advantage was not significant, although there was a trend in favor of postoperative chemotherapy", based on our systematic review and meta-analysis of IPD (PMID: 9400508)
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.1.2017 Soft Tissue Sarcoma
Description Sarcoma CT IPD (PMID:9400508) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.2.2019 Soft Tissue Sarcoma
Description Sarcoma CT IPD (PMID:9400508) NCCN guideline 2019
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title UK guidelines for the management of soft tissue sarcomas
Description Sarcoma CT IPD (PMID:9400508, PMID: 10796873) BSG guideline 2016
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.1.2015 Soft Tissue Sarcoma
Description Sarcoma CT SR (PMID:7640234) NCCN guideline 2015
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of summary data was cited as key evidence in this guideline (PMID: 7640234)
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.1.2016 Soft Tissue Sarcoma
Description Sarcoma CT SR (PMID:7640234) NCCN guideline 2016
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact Our systematic review and meta-analysis of summary data was cited as key evidence in this guideline (PMID: 7640234)
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.1.2017 Soft Tissue Sarcoma
Description Sarcoma CT SR (PMID:7640234) NCCN guideline 2017
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.1.2018 Soft Tissue Sarcoma
Description Sarcoma CT SR (PMID:7640234) NCCN guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.1.2018 Soft Tissue Sarcoma
Description Sarcoma CT SR (PMID:7640234) NCCN guideline 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title NCCN Clinical Practice Guidelines in Oncology v.2.2019 Soft Tissue Sarcoma
Description Sarcoma CT SR (PMID:7640234) NCCN guideline 2019
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Description AstraZeneca support for start-up of RAMPART renal cancer adjuvant trial
Amount £694,715 (FKP)
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 04/2016 
End 12/2017
 
Description CRUK / CTAAC funding for EURAMOS-1 --> U122861384 (one of many co-funders for many destinations --> approx UK total shown)
Amount £500,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2005 
End 06/2014
 
Description CTAAC funding for Add-Aspirin
Amount £3,598,674 (GBP)
Funding ID C471/A15015 
Organisation Cancer Research UK 
Department CTAAC Clinical Trials Advisory & Awards
Sector Charity/Non Profit
Country United Kingdom
Start 01/2013 
End 12/2023
 
Description CTAAC funding for Add-Aspirin sample collection
Amount £404,910 (GBP)
Funding ID C471/A19252 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2015 
End 06/2025
 
Description CTAAC funding for PATCH extension
Amount £1,288,426 (GBP)
Funding ID C17093/A12443 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2010 
End 03/2021
 
Description Clinical Research Committee - funding extension for TRISST trial
Amount £228,700 (GBP)
Funding ID C17084/A8690 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2017 
End 03/2021
 
Description Clinical Trial Fellowship at the MRC Clinical Trials Unit, UCL
Amount £126,985 (GBP)
Funding ID 26413 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2018 
End 01/2021
 
Description European Science Foundation funding for EURAMOS-1 --> U122861384 (one of many co-funders for many destinations --> approx UK total shown)
Amount £500,000 (GBP)
Funding ID CRUK/06/019 [A3804] - Cancer Research UK seems to consider this as one with the original grant. We did not expect this. 
Organisation European Science Foundation (ESF) 
Sector Charity/Non Profit
Country European Union (EU)
Start 01/2005 
End 12/2019
 
Description MRC research grant - the Re-IMAGINE consortium
Amount £6,347,795 (GBP)
Funding ID MR/R014043/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2018 
End 05/2022
 
Description MRC trial funding grant for EURAMOS-1 --> U122861384 (one of many co-funders for many destinations --> approx UK total shown)
Amount £500,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2005 
End 06/2015
 
Description NIHR (HTA) funding for Add-Aspirin
Amount £3,124,812 (GBP)
Funding ID 12/01/38 
Organisation National Institute for Health Research 
Department Health Technology Assessment Programme (HTA)
Sector Public
Country United Kingdom
Start 05/2014 
End 04/2023
 
Description PROMIS trial
Amount £1,786,862 (GBP)
Funding ID 09/22/67 
Organisation National Institute for Health Research 
Department Health Technology Assessment Programme (HTA)
Sector Public
Country United Kingdom
Start 06/2011 
End 11/2015
 
Description Population Research Committee - Catlyst Award
Amount £5,035,497 (GBP)
Funding ID C569/A24991 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2018 
End 01/2023
 
Description Prostate Cancer Charity -- RT01/PR07/The Prostate Cancer Charity, UK (via Institute of Cancer Research)
Amount £10,000 (GBP)
Organisation Prostate Cancer UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2010 
End 12/2014
 
Description RAMPART Clinical Trial - Collaboration with AZ
Amount $22,000,000 (USD)
Organisation AstraZeneca 
Department Astra Zeneca
Sector Private
Country United States
Start 06/2018 
End 12/2029
 
Title Add-Aspirin sample collection 
Description Participants in the Add-Aspirin trial are being asked to provide blood and tumour samples at the time of registration in the trial. Samples are being collected at two central laboratories. The collection was initiated when the trial opened to recruitment (October 2015) and is currently ongoing. This will provide a unique and valuable resource for future translational research, and a broad programme of work utilising the samples is being planned, including investigation of the mechanisms of action responsible for anti-cancer effects of aspirin and identification of biomarkers for aspirin efficacy and toxicity in this setting. 
Type Of Material Biological samples 
Provided To Others? No  
Impact No notable impacts as yet. Translational work utilising the samples is being planned. Other research groups will be able to gain access to the samples through a controlled-access process. 
 
Title OE05 sample collection 
Description Collection of blood and tumour samples from OE05 trial. 
Type Of Material Biological samples 
Provided To Others? No  
Impact Unknown 
 
Title PATCH sample collection 
Description In PATCH, blood and urine samples were collected at various time points during trial follow-up for consenting patients randomised up to end October 2013. Baseline blood samples for future research are also being collected in all consenting patients. All samples are stored at Charing Cross Hospital Assay Laboratory. 
Type Of Material Biological samples 
Provided To Others? No  
Impact These samples will be utilised in analyses to increase understanding of the underlying mechanisms for the potential benefits and adverse effects of the trial treatments, for example, for assessing changes in SHBG, oestrone/oestradiol ratio and bone biomarkers during time on treatment. 
 
Title TE23 sample collection 
Description Repositry of tumour and blood samples from participants in the TE23 trial. 
Type Of Material Biological samples 
Year Produced 2016 
Provided To Others? Yes  
Impact Other research groups are able to gain access to the samples through application to the Trial Steering Committee. To date, samples have been shared with a research group at Cambridge University who will use the samples to investigate diagnostic and prognostic blood-based microRNA markers, and other short non-coding RNA profiles, in testicular germ cell tumours. 
 
Title TRICON8 Sample Collection 
Description Participants in the ICON8 trial were invited to consent to a translational research substudy to provide blood, plasma and tumour samples at the same time as consent to the main trial. Participants could consent at one of three levels depending on their preference and hospital site's resources. Sample coordination, storage and preliminary analysis is undertaken by Cambridge University. Researchers will be able to access samples via a formal application process. This sample collection will represent a valuable resource for future translational work in ovarian cancer and will represent one of the largest bio-repositories for this disease area. 
Type Of Material Biological samples 
Provided To Others? No  
Impact No notable impacts as yet. Translational work utilising the samples is being planned. Other research groups will be able to gain access to the samples through a controlled-access process. 
 
Title TRICON8B Sample Collection 
Description Participants in the ICON8B trial will be invited to consent to a translational research substudy to provide blood, plasma and tumour samples at the same time as consent to the main trial. Participants will be invited to consent at one of three levels depending on their preference and hospital site's resources. Sample coordination, storage and preliminary analysis is undertaken by Cambridge University. Dr James Brenton at Cambridge University has secured a CRUK grant for the funding of TRICON8B. Sample collection is planned to commence in q2 of 2016. Researchers will be able to access samples via a formal application process. This sample collection will represent a valuable resource for future translational work in ovarian cancer and will represent one of the largest bio-repositories for this disease area. 
Type Of Material Biological samples 
Provided To Others? No  
Impact No notable impacts as yet. Translational work utilising the samples is being planned. Other research groups will be able to gain access to the samples through a controlled-access process. 
 
Title TRISST clinical trial database 
Description Data collected specifically to allow monitoring and analysis of the primary research questions addressed by the TRISST trial. The database also includes data relevant not only to the primary question, but which provides a unique resource with which to address related questions. External groups may request access to the data through the independent Trial Steering Committee 
Type Of Material Improvements to research infrastructure 
Provided To Others? No  
Impact Trial is ongoing. The database is currently used for ongoing data collection, checking and monitoring. 
 
Title Urine sample collection in Add-Aspirin trial 
Description Urine samples are being collected at 3 time point from a subgroup of participants (n=500) in the Add-Aspirin trial. The primary purpose of the collection is to investigate platelet function (by measuring thromboxane B2) as a potential mechanism of action for anti-cancer effects of aspirin; but further translational projects utilising the samples may be developed, and the collection will be made available to other researchers (via a controlled access approach) in due course. 
Type Of Material Biological samples 
Year Produced 2018 
Provided To Others? No  
Impact None as yet. 
 
Title Add-Aspirin trial database 
Description A secure database with built in checks/validations, as well as functionality for producing reports, has been developed in-house to record all data collected in the trial. 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact Due to the size and scope of the planned trial (>10,000 participants with four different tumour types), the database is expected to provide a rich resource of information for use in future research beyond the original trial question. The data will be made available to other researchers via an application process. 
 
Title Add-Aspirin trial drug supply management system 
Description A drug supply management system initially developed to coordinate the drug supply in the Add-Aspirin trial (double-blind, randomised, controlled trial) with the flexibility to be adapted for other trials. 
Type Of Material Data handling & control 
Provided To Others? No  
Impact None 
 
Title BR14 - Health Economics Database 
Description As requested by CTAAC, we have collected data to permit a cost effectiveness analysis in UK patients. The EORTC did not wish to include this in all patients but the expectation is that there will be sufficient UK patients to enable a reliable analysis to be carried out, and the methodology applied to the analysis will be made available to other national collaborating groups who may wish to carry out their own analysis on a country-specific basis. 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact None to date - analysese will be carried out at the end of the study. 
 
Title Clinical database (OE05) 
Description Clinical database for OE05 trial (neo-adjuvant chemotherapy for oesophageal adenocarcinoma). 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact Not yet known. 
 
Title Clinical database (QUARTZ) 
Description Clinical database for QUARTZ (Quality of life after treatment for brain metastases). 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact Main trial paper published. Data available for internal and external use. 
 
Title ICON6 tumour specimen collection & associated clinical data 
Description Specimens from this completed clinical trial in 2nd line ovarian cancer, along with anonymised demographic and outcome data 
Type Of Material Database/Collection of data 
Year Produced 2015 
Provided To Others? Yes  
Impact 1st use of this collection not yet completed 
 
Title ICON7 trial specimen collection and corresponding clinical database 
Description Tumour and blood specimen collection from this ovarian cancer trial, along with anonymised corresponding demographic and clinical outcome data. 
Type Of Material Database/Collection of data 
Year Produced 2010 
Provided To Others? Yes  
Impact Multiple publications, listed as publication outputs 
 
Title ICON8 Trial Database 
Description A secure database with built in checks/validations, as well as functionality for producing reports, has been developed in-house to record all data collected in the trial. 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact No impact yet. The data will be made available to other researchers via an application process. 
 
Title ICON8B Trial Database 
Description A secure database with built in checks/validations, as well as functionality for producing reports, has been developed in-house to record all data collected in the trial. 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact No impact yet. The data will be made available to other researchers via an application process. 
 
Title PATCH and NICOR/HES cardiovascular outcome data linkage 
Description Cardiovascular (CVS) safety is as an important secondary endpoint within the PATCH trial. Detailed information on CVS outcomes are thus collected and regularly reviewed, which is challenging and time consuming, as it requires frequent exchanges of SAE forms and documentation between participating centres and the trial team. A pilot study will be undertaken to compare the CVS outcome data from the trial database with information from the National Institute for Cardiovascular Outcomes Research (NICOR) and the Hospital Episode Statistics (HES) databases for the patients already enrolled in PATCH, to validate methodology and data capture. 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact No impact yet as this work is currently in development. 
 
Title PATCH trial database 
Description A secure database with built in checks/validations, as well as functionality for producing reports, has been developed in-house to record all data collected in the trial. 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact No impact yet. The data will be made available to other researchers via an application process. 
 
Description A review of RCTs in recurrent ovarian cancer 
Organisation University College London Hospital
Department University College London Hospitals Charity (UCLH)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Carried out searches for trials and reviewed the results, early stage protocol development
Collaborator Contribution Reviewed results of searches and early stage protocol development
Impact Protocol in development
Start Year 2014
 
Description Add-Aspirin - Sir Dorabji Tata Trust 
Organisation Sir Dorabji Tata Trust
Country India 
Sector Charity/Non Profit 
PI Contribution Our team is leading the international Add-Aspirin clinical trial in collaboration with a group at the Tata Memorial Centre who will lead the trial in India.
Collaborator Contribution The Sir Dorabji Tata Trust has agreed to provide funding to the Tata Memorial Centre to run the Add-Aspirin trial in India.
Impact Securing this funding has meant that the Add-Aspirin trial can open in India. Set-up activities are currently underway.
Start Year 2015
 
Description Add-Aspirin - Tata Memorial Hospital 
Organisation Tata Memorial Hospital
Country India 
Sector Hospitals 
PI Contribution Leading the Add-Aspirin trial; management of the trial in the UK; oversight and mentoring of the research group at the Tata Memorial Hospital who will manage Indian participation in the trial.
Collaborator Contribution Management and oversight of the Add-Aspirin trial in India.
Impact In terms of the Add-Aspirin trial, the collaboration will speed up delivery of the research and enable demonstration of the health intervention in a range of settings, increasing the potential global impact of the results. Additionally, the work is facilitating development of a cancer research network in India and will pave the way for future collaborative projects.
Start Year 2013
 
Description Add-Aspirin - Tayside tissue Bank 
Organisation University of Dundee
Department Tayside Biorepository
Country United Kingdom 
Sector Academic/University 
PI Contribution We are leading and co-ordinating the Add-Aspirin clinical trial and the associated collection of biological samples from trial participants.
Collaborator Contribution Tayside Tissue Bank will host the Add-Aspirin sample collection in the UK (jointly with Wales Cancer Bank) - receiving, processing and storing samples from participating trial sites.
Impact The trial sample collection was initiated at the time that the trial opened to recruitment (October 2015) - collection of samples is currently ongoing. Translational work utilising the samples is being planned.
Start Year 2015
 
Description Add-Aspirin - Wales Cancer Bank 
Organisation Wales Cancer Bank
Country Unknown 
Sector Academic/University 
PI Contribution We are leading and co-ordinating the Add-Aspirin clinical trial and the associated collection of biological samples from trial participants.
Collaborator Contribution Wales Cancer Bank will host the Add-Aspirin sample collection in the UK (jointly with Tayside Tissue Bank) - receiving, processing and storing biological samples from participating trial sites.
Impact The sample collection was initiated at the time that the trial opened to recruitment (October 2015) and collection of samples is currently ongoing. Translational work utilising the collection is being planned.
Start Year 2015
 
Description Add-Aspirin collaboration with Cancer Trials Ireland 
Organisation Cancer Trials Ireland
Country Ireland 
Sector Charity/Non Profit 
PI Contribution Chief Investigator and trials unit team responsible for running the Add-Aspirin clinical trial.
Collaborator Contribution Delegated responsibilities for set-up and coordination of approximately 13 Irish centres that will recruit to the Add-Aspirin trial.
Impact Participation of 13 Irish centres in the Add-Aspirin trial
Start Year 2018
 
Description Add-Aspirin trial - Alcura Ltd 
Organisation Alcura
Country United Kingdom 
Sector Private 
PI Contribution Following an EU tender, a contract has been agreed with Alcura Ltd to package, label and distribute the run-in and blinded Add-Aspirin trial medication to all centres in the UK and India. Contract negotiations are now close to completion. The trial team have developed an in-house drug supply system which will be accessed to manage packaging and distribution by Alcura Ltd.
Collaborator Contribution Alcura Ltd will package, label and distribute the run-in and blinded Add-Aspirin trial medication to all centres in the UK and India.
Impact No outputs yet. The trial is currently in set-up.
Start Year 2014
 
Description Add-Aspirin trial - Bayer Pharmaceuticals PLC 
Organisation Bayer
Department Bayer HealthCare
Country Germany 
Sector Private 
PI Contribution We approached Bayer to supply the drugs for the Add-Aspirin trial.
Collaborator Contribution Bayer Pharmaceuticals are supplying the Add-Aspirin trial medication (100mg aspirin tablets, 300mg aspirin tablets and matched placebos) free of charge.
Impact Contract signed, no output to date. The trial is currently in set-up.
Start Year 2014
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation British Columbia Cancer Agency (BCCA)
Department Fraser Valley Cancer Centre
Country Canada 
Sector Public 
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation EORTC
Country Belgium 
Sector Charity/Non Profit 
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation Essen University Hospital
Country Germany 
Sector Academic/University 
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation Freeman Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation Herlev Hospital
Country Denmark 
Sector Hospitals 
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation Hospital La Luz
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation Queen Elizabeth Hospital Birmingham
Country United Kingdom 
Sector Hospitals 
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation Regina Elena National Cancer Institute
Country Italy 
Sector Hospitals 
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation Regional Hospital San Camillo-Forlanini
Country Italy 
Sector Hospitals 
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation Royal Marsden Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation Sapienza University of Rome
Country Italy 
Sector Academic/University 
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation The Christie Hospital
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation USC Norris Cancer Hospital
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation University of Chicago
Country United States 
Sector Academic/University 
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation Uppsala University Hospital
Country Sweden 
Sector Hospitals 
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis 
Organisation Virgen del Rocio University Hospital
Country Spain 
Sector Hospitals 
PI Contribution For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing.
Collaborator Contribution Collaboration in original IPD meta-analysis or protocol development and provision of data for this update
Impact 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650)
 
Description AstraZeneca start-up funding toward RAMPART international renal cancer adjuvant trial 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution An international consortium of key investigators in this field and a novel trial design
Collaborator Contribution Provision of start-up funds and drug information in support of the planned trial (which will itself have further funding)
Impact Development of trial underway and in discussion with regulatory authorities
Start Year 2016
 
Description BR13 Collaborations 
Organisation European Organisation for Research and Treatment of Cancer (EORTC)
Country European Union (EU) 
Sector Charity/Non Profit 
PI Contribution The MRC Clinical Trials Unit at UCL coordinates the UK involvement in this Intergroup collaborative trial, with responsibilty for gaining and maintaining National Ethics and Regulatory approvals, and UK site approvals and initiation. Data chases and queries are relayed to and from participating UK sites via the CTU, who will intervene as required if a site is identified as performing poorly. As a result a much larger number of UK sites were able to participate (including those where the PI is not a member of the participating EORTC groups). Dr Jeremy Rees acts as the UK Chief Investigator.
Collaborator Contribution The EORTC is the lead organisation and Sponsor for this trial, and oversees all participating international groups, delegating some responsibilities for the trial in the UK to the MRC CTU. The EORTC is responsible in particular for developing and maintaining the clinical trial database, and will be responsible for the trial analysis. The NCRI brain tumour CSG members supported and promoted the trial; the (former) NCRN provided the infrastructure to allow all the UK collaborating sites to take part in the trial.
Impact The collaboration enabled the clinical trial to be completed, a database of the clinical data and accompanying sample collection to be developed and maintained, and initial results to be disseminated.
Start Year 2006
 
Description BR13 Collaborations 
Organisation National Cancer Research Institute (NCRI)
Department NCRI Brain Tumour CSG
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution The MRC Clinical Trials Unit at UCL coordinates the UK involvement in this Intergroup collaborative trial, with responsibilty for gaining and maintaining National Ethics and Regulatory approvals, and UK site approvals and initiation. Data chases and queries are relayed to and from participating UK sites via the CTU, who will intervene as required if a site is identified as performing poorly. As a result a much larger number of UK sites were able to participate (including those where the PI is not a member of the participating EORTC groups). Dr Jeremy Rees acts as the UK Chief Investigator.
Collaborator Contribution The EORTC is the lead organisation and Sponsor for this trial, and oversees all participating international groups, delegating some responsibilities for the trial in the UK to the MRC CTU. The EORTC is responsible in particular for developing and maintaining the clinical trial database, and will be responsible for the trial analysis. The NCRI brain tumour CSG members supported and promoted the trial; the (former) NCRN provided the infrastructure to allow all the UK collaborating sites to take part in the trial.
Impact The collaboration enabled the clinical trial to be completed, a database of the clinical data and accompanying sample collection to be developed and maintained, and initial results to be disseminated.
Start Year 2006
 
Description BR13 Collaborations 
Organisation National Cancer Research Institute (NCRI)
Department National Cancer Research Network (NCRN)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution The MRC Clinical Trials Unit at UCL coordinates the UK involvement in this Intergroup collaborative trial, with responsibilty for gaining and maintaining National Ethics and Regulatory approvals, and UK site approvals and initiation. Data chases and queries are relayed to and from participating UK sites via the CTU, who will intervene as required if a site is identified as performing poorly. As a result a much larger number of UK sites were able to participate (including those where the PI is not a member of the participating EORTC groups). Dr Jeremy Rees acts as the UK Chief Investigator.
Collaborator Contribution The EORTC is the lead organisation and Sponsor for this trial, and oversees all participating international groups, delegating some responsibilities for the trial in the UK to the MRC CTU. The EORTC is responsible in particular for developing and maintaining the clinical trial database, and will be responsible for the trial analysis. The NCRI brain tumour CSG members supported and promoted the trial; the (former) NCRN provided the infrastructure to allow all the UK collaborating sites to take part in the trial.
Impact The collaboration enabled the clinical trial to be completed, a database of the clinical data and accompanying sample collection to be developed and maintained, and initial results to be disseminated.
Start Year 2006
 
Description Barts Chemotherapy Response Score Collaboration 
Organisation St Bartholomew's Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution Organisational input, provision of samples (omental slides) and future corresponding data
Collaborator Contribution Validation of CRS system and funding of this project.
Impact No outputs at present
Start Year 2015
 
Description Canadian (CCTG) collaboration on FOCUS4 
Organisation Canadian Cancer Trials Group
Country Canada 
Sector Hospitals 
PI Contribution Provision of a platform for biomarker stratification and an open trial that becomes the first Canada-wide stratified medicine cancer trial
Collaborator Contribution It was hoped that Canadian recruiting to FOCUS4 could begin in 2017 but they have run into funding difficulties and this arrangement is currently up in the air.
Impact No outputs as yet as ultimately Canadian funding for this collaboration was not obtained
Start Year 2016
 
Description Collaboration on health economics analysis in TRISST trial 
Organisation University of York
Department Centre for Health Economics (CHE)
Country United Kingdom 
Sector Academic/University 
PI Contribution Design, conduct and management of the TRISST clinical trial
Collaborator Contribution Performing health economics analyses for the TRISST clinical trial, alongside the primary (efficacy) analyses
Impact No outputs to date. This is a multi-disciplinary collaboration between the TRISST Trial Management Group - which includes clinicians, statisticians and trialists - and colleagues at York University with expertise in health economics.
Start Year 2008
 
Description Collaboration with AstraZeneca on cedaranib following ICON6 trial outcome 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Sponsored and ran the ICON6 trial after AZ abandoned development of this compound. Now working with them to produce licensing application. Anticipate considerable research support plus drug supply for trials to follow.
Collaborator Contribution Drug supply only until positive outcome of the study was reported. Subsequently, close colloaboration on preparation of regulatory package.
Impact Full study report in development
Start Year 2007
 
Description EORTC - BR14 
Organisation European Organisation for Research and Treatment of Cancer (EORTC)
Country European Union (EU) 
Sector Charity/Non Profit 
PI Contribution The MRC CTU at UCL contributed to statistical design of the study during initial design dicussions and oversees and facilitate UK participant through an intergroup agreement with the EORTC. We are responsbile for ethics and regulatory approval and reporting and UK site management. As a result of our involvement any approved UK site may participate in the trial without this only EORTC member sites would be able to take part substanitally limiting accrual.
Collaborator Contribution Intergroup collaboration has enabled this trial, which is in a relatively rare type of brain tumour to take place. The overall trial co-ordination and sponsorship is taken by the EORTC.
Impact The trial completed recruitment in 2015.
Start Year 2008
 
Description EURAMOS 
Organisation Cooperative Osteosarcoma Study Group
Country European Union (EU) 
Sector Academic/University 
PI Contribution Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining.
Collaborator Contribution Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.
Impact No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).
 
Description EURAMOS 
Organisation European and American Osteosarcoma Study Group (EURAMOS)
Department European Osteosarcoma Group (EOI)
Country United Kingdom 
Sector Academic/University 
PI Contribution Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining.
Collaborator Contribution Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.
Impact No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).
 
Description EURAMOS 
Organisation Merck
Department Schering Plough
Country United States 
Sector Public 
PI Contribution Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining.
Collaborator Contribution Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.
Impact No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).
 
Description EURAMOS 
Organisation Merck
Country Germany 
Sector Private 
PI Contribution Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining.
Collaborator Contribution Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.
Impact No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).
 
Description EURAMOS 
Organisation National Cancer Institute (NCI)
Department Children's Oncology Group (COG)
Country United States 
Sector Academic/University 
PI Contribution Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining.
Collaborator Contribution Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.
Impact No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).
 
Description EURAMOS 
Organisation National Cancer Research Institute (NCRI)
Department NCRI Bone Cancer CSG
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining.
Collaborator Contribution Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.
Impact No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).
 
Description EURAMOS 
Organisation National Cancer Research Institute (NCRI)
Department National Cancer Research Network (NCRN)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining.
Collaborator Contribution Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.
Impact No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).
 
Description EURAMOS 
Organisation Scandinavian Sarcoma Group (SSG)
Country Sweden 
Sector Charity/Non Profit 
PI Contribution Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining.
Collaborator Contribution Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.
Impact No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).
 
Description Gynecologic Cancer InterGroup (GCIG) 
Organisation Gynecologic Cancer InterGroup (GCIG)
Country Canada 
Sector Charity/Non Profit 
PI Contribution The Gynecologic Cancer Intergroup is an international collaboration of clinical trialists, whose aims are to promote and conduct high quality clinical trials in order to improve outcomes for women with gynecologic cancer. The MRC CTU contributes strongly to this collaboration with the majority of our trials being badged as GCIG trials. The contributions of this group include providing a forum for discussion on clinical trial development and prioritisation of research questions, harmonisation of clinical trial operations, participation in international clinical trial recruitment and meta-analyses.
Collaborator Contribution Collaboration in trials and harmonisation of processes and procedures
Impact Completion of recruitment of ICON7 trial from over 300 clinical sites in 11 countries. Publication of results from ICON5 trial, a GCIG collaboration with UK, US, Italy, Australia and New Zealand (pub med 19224846). Recruitment to ICON6 trial (currently open in UK and Canada). Recruitment to ICON8 trial (currently open in Korea and UK). International collaboration on clinical trials as outlined in publication 19720905
 
Description ICON8 trial (NCT10356837) 
Organisation Australia and New Zealand Gynaecological Oncology Group
Country Australia 
Sector Charity/Non Profit 
PI Contribution Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer
Collaborator Contribution CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.
Impact Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.
Start Year 2010
 
Description ICON8 trial (NCT10356837) 
Organisation Cancer Research UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer
Collaborator Contribution CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.
Impact Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.
Start Year 2010
 
Description ICON8 trial (NCT10356837) 
Organisation European Society of Gynaecological Oncology (ESGO)
Department European Network of Gynaecological Oncology Trials Groups (ENGOT)
Country European Union (EU) 
Sector Academic/University 
PI Contribution Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer
Collaborator Contribution CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.
Impact Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.
Start Year 2010
 
Description ICON8 trial (NCT10356837) 
Organisation Gynecologic Cancer InterGroup (GCIG)
Country Canada 
Sector Charity/Non Profit 
PI Contribution Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer
Collaborator Contribution CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.
Impact Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.
Start Year 2010
 
Description ICON8 trial (NCT10356837) 
Organisation Irish Clinical Oncology Research Group (ICORG)
Country Ireland 
Sector Charity/Non Profit 
PI Contribution Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer
Collaborator Contribution CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.
Impact Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.
Start Year 2010
 
Description ICON8 trial (NCT10356837) 
Organisation Korean Gynaecological Oncology Group
Country Korea, Republic of 
Sector Charity/Non Profit 
PI Contribution Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer
Collaborator Contribution CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.
Impact Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.
Start Year 2010
 
Description ICON8 trial (NCT10356837) 
Organisation National Cancer Research Institute (NCRI)
Department NCRI Gynaecological Oncology CSG
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer
Collaborator Contribution CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.
Impact Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.
Start Year 2010
 
Description ICON8 trial (NCT10356837) 
Organisation Research Group on Ovarian Cancer and Gynecologic Tumors of Mexico (GICOM)
Country Mexico 
Sector Charity/Non Profit 
PI Contribution Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer
Collaborator Contribution CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.
Impact Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.
Start Year 2010
 
Description PATCH bone biomarker sub-study 
Organisation Imperial College London
Department Imperial College Trust
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution We are working with Dr Richie Abel, who is a lecturer in Musculoskeletal Sciences, on a proposal to compare changes in bone biomarkers between treatment arms (oestrogen patches vs LHRHa) within the PATCH trial.
Collaborator Contribution Dr Richie Abel is leading on the proposal and will coordinate the analysis of the stored serum samples.
Impact The proposal is currently in development.
Start Year 2015
 
Description PATCH trial Progynova sub-study - Bayer Plc 
Organisation Bayer
Department Bayer HealthCare
Country Germany 
Sector Private 
PI Contribution We approached Bayer Plc to supply the Progynova oestrogen patches for a sub-study within the main PATCH trial.
Collaborator Contribution Bayer Plc will provide the Progynova patches at a 37% discount price, and will ensure the supply of the patches for the sub-study.
Impact Ninety patients were recruited to the sub-study from 9 sites. In the final analysis, the 12-weeks castration rate (testosterone =1.7nmol/L) in the Progynova arm was 100%, confirming these patches can effectively achieve castrate levels of testosterone within this setting at a similar dose regimen to that used for FemSeven patches.
Start Year 2015
 
Description RADICALS (MRC PR10) trial (NCT00541047) 
Organisation Canadian Cancer Society
Department Canadian Cancer Society Research Institute
Country Canada 
Sector Academic/University 
PI Contribution Design, central coordination and analysis of the RADICALS trial
Collaborator Contribution Coordination of RADICALS trial in Canada This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial
Impact Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC).
Start Year 2006
 
Description RADICALS (MRC PR10) trial (NCT00541047) 
Organisation Cancer Research UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Design, central coordination and analysis of the RADICALS trial
Collaborator Contribution Coordination of RADICALS trial in Canada This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial
Impact Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC).
Start Year 2006
 
Description RADICALS (MRC PR10) trial (NCT00541047) 
Organisation National Cancer Research Institute (NCRI)
Department NCRI Prostate Cancer CSG
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Design, central coordination and analysis of the RADICALS trial
Collaborator Contribution Coordination of RADICALS trial in Canada This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial
Impact Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC).
Start Year 2006
 
Description RADICALS (MRC PR10) trial (NCT00541047) 
Organisation National Cancer Research Institute (NCRI)
Department National Cancer Research Network (NCRN)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Design, central coordination and analysis of the RADICALS trial
Collaborator Contribution Coordination of RADICALS trial in Canada This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial
Impact Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC).
Start Year 2006
 
Description RADICALS and Canada 
Organisation National Cancer Institute of Canada Clinical Trials Group
Country Canada 
Sector Public 
PI Contribution RADICALS trial is led from MRC CTU at UCL
Collaborator Contribution Canadian sites have engaged in recruiting, treating and following-up patients. This has been organised by the Canadian Cancer Trials Group.
Impact Results from the trial will follow on 2018 to 2020
Start Year 2007
 
Description RADICALS and Denmark 
Organisation Danish Cancer Society
Country Denmark 
Sector Charity/Non Profit 
PI Contribution RADICALS trial is led from MRC CTU at UCL
Collaborator Contribution Danish sites in Copenhagen, Aarhus and elsewhere have collaborated in recruiting, treatment and following-up patients
Impact Results to follow 2018-2020
Start Year 2010
 
Description Second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis 
Organisation Royal Sussex County Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution Searched for and categorised trials, analysed results, interpreted results and wrote manuscript
Collaborator Contribution Contributed to project design and manuscript
Impact 1 publication (PMID: 30482913)
Start Year 2015
 
Description Staging accuracy in non-small cell lung cancer 
Organisation Addenbrooke's Hospital
Department Department of Oncology
Country United Kingdom 
Sector Hospitals 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation Antwerp University Hospital
Country Belgium 
Sector Hospitals 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation Germans Trias i Pujol University Hospital
Country Spain 
Sector Academic/University 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation Guangdong General Hospital
Country China 
Sector Hospitals 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation Gustave-Roussy Institute
Country France 
Sector Multiple 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation Helsinki University Central Hospital
Country Finland 
Sector Hospitals 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation Pitié-Salpêtrière Hospital
Country France 
Sector Hospitals 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation University College London Hospitals NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation University Hospital of Besancon
Country France 
Sector Hospitals 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation University Hospitals of Leicester NHS Trust
Country United Kingdom 
Sector Public 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation University Medical Center Gronigen
Country Netherlands 
Sector Hospitals 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation University of Colorado
Department Cancer Centre
Country United States 
Sector Academic/University 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation University of Texas
Country United States 
Sector Academic/University 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation University of Turin
Country Italy 
Sector Academic/University 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation University of York
Country United Kingdom 
Sector Academic/University 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation Vanderbilt University
Country United States 
Sector Academic/University 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description Staging accuracy in non-small cell lung cancer 
Organisation Yokohama City University Medical Centre
Country Japan 
Sector Hospitals 
PI Contribution The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript
Collaborator Contribution The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project
Impact 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190)
Start Year 2006
 
Description TE23 data and sample sharing - University of Cambridge 
Organisation University of Cambridge
Department Department of Pathology
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of biological samples and data collected within the TE23 clinical trial in testicular cancer
Collaborator Contribution Undertaking a project utilising the data and samples from the TE23 clinical trial
Impact None
Start Year 2016
 
Description TRICON8B 
Organisation Cancer Research UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution We will facilitate entry of patients consenting to the ICON8B trial into the associated translational studies and keep records of samples collected via the Translational Research CRF.
Collaborator Contribution Collection, handling, storage and preliminary analysis of blood and tissue samples collected from consenting ICON8B patients.
Impact Establishment of a tissue bank linked to the ICON8 trial
Start Year 2016
 
Description TRISST trial 
Organisation National Cancer Research Institute (NCRI)
Department NCRI Testis Tumour CSG
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Trial design, coordination and analysis
Collaborator Contribution This trial is a collaboration with the NCRN which provides infrastructure support for conducting studies across the UK. The participating sites are responsible for the identification, consent and entry of patients into the trial, administration of trial procedures and provision of patient data. The NCRI Testis Cancer CSG has helped support the set up of the trial and helps promote collaboration and participation.
Impact Ongoing. This is a multi-disciplinary collaboration including clinicians and research nurses at participating sites, as well as statisticians and trial/data management staff at the trials unit.
Start Year 2008
 
Description TRISST trial 
Organisation National Cancer Research Institute (NCRI)
Department National Cancer Research Network (NCRN)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Trial design, coordination and analysis
Collaborator Contribution This trial is a collaboration with the NCRN which provides infrastructure support for conducting studies across the UK. The participating sites are responsible for the identification, consent and entry of patients into the trial, administration of trial procedures and provision of patient data. The NCRI Testis Cancer CSG has helped support the set up of the trial and helps promote collaboration and participation.
Impact Ongoing. This is a multi-disciplinary collaboration including clinicians and research nurses at participating sites, as well as statisticians and trial/data management staff at the trials unit.
Start Year 2008
 
Description TransMAGIC - CLOVIS 
Organisation Clovis Oncology, inc
Country United States 
Sector Private 
PI Contribution Supply of tumour samples and clinical data from MAGIC. At a later date will be involved in reviewing the output of the work.
Collaborator Contribution Will be analysing the tumour samples, and performing statistical analysis on the data.
Impact Collaboration only recently started, so no output yet.
Start Year 2015
 
Description UCL - Astra Zeneca: RAMPART Trial - Main Collaboration Agreement 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution MRC CTU at UCL has led on the design of this trial, is leading on all aspects of trial conduct and will lead on all aspects of trial analysis, reporting and the dissemination of results.
Collaborator Contribution Astra Zeneca have agreed to provide USD$22,000,000 to support the cost of the trial. They are also providing free trial drugs to sites (including cost of distribution).
Impact No outputs to date.
Start Year 2018
 
Description UCL - Kidney Cancer UK - RAMPART Trial 
Organisation Kidney Research UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution MRC CTU at UCL has led on the design of the RAMPART trial, is leading on all aspects of trial conduct and will lead on all aspects of trial analysis, reporting and the dissemination of results.
Collaborator Contribution Kidney Cancer UK peer-reviewed and approved the RAMPART trial, consequently the trial was adopted onto the NCRI trials portfolio. Kidney Cancer UK have agreed to provide funding to support patient-centred activities.
Impact No outcomes to date
Start Year 2018
 
Description Vitamin D as a cancer therapy 
Organisation Brighton and Sussex University Hospitals NHS Trust
Country United Kingdom 
Sector Public 
PI Contribution Assisted in searching for trials, categorised trials, tabulated results, contributed to manuscript and interpretation of results
Collaborator Contribution Collated information and wrote the majority of the manuscript
Impact One manuscript published (PMID: 26520788)
Start Year 2014
 
Title Add-Aspirin clinical trial 
Description The Add-Aspirin trial opened to recruitment in the UK in 2015 - it will investigate whether regular aspirin following treatment for an early stage common cancer can prevent recurrence and improve survival. Recruitment is currently ongoing. Funding for the trial is being provided by Cancer Research UK and the NIHR Heath Technology Assessment Programme. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2015
Development Status Under active development/distribution
Impact None as yet. 
URL http://www.addaspirintrial.org/
 
Title ICON8B 
Description A phase III randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer. Submitted as an amendment to the ICON8 protocol. First site opened to recruitment in July 2015. Recruitment on going as of February 2017 (expected to complete recruitment in July 2019). The trial is funded by CRUK and the MRC. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2015
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Pending 
URL http://www.isrctn.com/ISRCTN10356387?q=&filters=recruitmentCountry:Mexico&sort=relevance&offset=73&t...
 
Title PATCH trial 
Description PATCH is a randomised, non-inferiority, phase III trial comparing the clinical efficacy and side effect profile of transdermal oestradiol (tE2) with Luteinising Hormone Releasing Hormone agonists (LHRHa) in the treatment of locally advanced and metastatic prostate cancer. Transdermal oestradiol avoids first-pass hepatic metabolism and therefore is not expected to be associated with the cardiovascular (CVS) toxicity previously seen with oral oestrogen. It also avoids some of the serious side-effects associated with LHRHa. The primary outcome measures will be overall survival and progression-free survival. The secondary outcome measures include prostate cancer specific survival, hormone levels, CVS and other toxicity, and quality of life. Data from the trial so far have shown promising evidence of the safety and efficacy of tE2. Results from the first stage of the trial have been published (n= 254), showing tE2 produced castrate levels of testosterone similar to LHRHa, with no evidence of excess CVS toxicity. During the second stage, a pre-planned interim analysis (n=638) reviewed by the Independent Data Monitoring Committee in June 2013 led to the trial being extended for a phase III evaluation of the efficacy of tE2. Since June 2017, a new tE2 comparison has been added to the STAMPEDE trial platform to compare tE2 against standard methods for androgen deprivation therapy, to complement the PATCH trial. The clinical efficacy of tE2 will henceforth be evaluated using relevant data from the PATCH and STAMPEDE trials combined, using a meta-analysis approach. This efficient approach enables faster recruitment to the comparison and activation of the comparison at additional UK sites. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2013
Development Status Under active development/distribution
Impact Results from a bone health sub-study embedded within PATCH have shown tE2 protects against the bone mineral density loss seen with LHRHa. In addition, patients on tE2 appear to develop more favourable metabolic profiles and have a number of improved short-term quality of life outcomes compared to those on LHRHa therapy. However, the clinical efficacy of tE2 needs confirming within a phase III trial setting before they can be considered as part of standard care in prostate cancer. 
 
Title PATCH trial Progynova sub-study 
Description Until recently, the patch brand solely used in the PATCH trial was FemSeven. However, it is known that there are differences in the pharmacokinetic properties between different brands of patches. Therefore, a small sub-study embedded within the main trial is currently underway to evaluate an alternative brand of patches, namely the Progynova TS. This is to confirm the appropriate dose regimen for the Progynova for achieving castrate levels of testosterone within this setting. The primary outcome measure is castration rate at 12 weeks. Approximately 70 patients are to be randomised in allocation ratio 2:1 of patches:LHRHa. The sub-study is expected to be completed around end 2016. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2015
Development Status Under active development/distribution
Impact Results from the sub-study will be important for ensuring the long-term supply of the patches for the main PATCH trial, and broaden the re-purposing element of the study. 
 
Title PROMIS MRI methods and description of needed validation for widespread use 
Description The MRC PROMIS trial established clearly the potential benefit, and the cost-effectiveness, of an MRI imaging step between identification of patients as possibly needing a prostate biopsy and the trans-rectal biopsy procedure itself. What remains to be done to ascertain whether high quality imaging and consistent radiographic interpretation in high volume can be implemented widely across the NHS. 
Type Diagnostic Tool - Imaging
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2016
Development Status Under active development/distribution
Clinical Trial? Yes
Impact
 
Title TRISST (TE24) 
Description Surveillance is an increasingly widely used management option for patients with stage I testicular seminoma, but requires regular radiological surveillance in order to detect recurrences early. CT scans are most widely used, but frequency varies considerably, and radiation associated with their use is a serious concern in this young, good prognosis population. The TRISST trial is factorial non-inferiority trial looking at 2 ways of potentially reducing radiation associated with surveillance scanning: a reduced scan frequency and/or replacement of CT scans with MRI scans. The trial is currently open to recruitment, due to complete in 2014, and is funded by CR UK 
Type Diagnostic Tool - Imaging
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2008
Development Status Under active development/distribution
Clinical Trial? Yes
Impact None as yet - this is the only randomised trial addressing these questions. 
URL http://www.isrctn.com/ISRCTN65987321
 
Title Add-Aspirin Drug Supply Management System 
Description A drug supply management system tailored to the trial requirements has been developed in-house to provide a secure system for coordinating all aspects of the drug supply process in the study. The drug packaging and distribution team, as well as research staff and pharmacists at participating sites will have web-based access to the system, and it will allow close oversight of the whole process by the Trials Unit team. Input from all of the relevant parties has been sought in developing the system and it has been designed in such a way that it can subsequently be adapted for use in future trials conducted at the unit. 
Type Of Technology Software 
Year Produced 2014 
Impact This in-house system may replace the need to out-source the management of drug supply processes, and so will have cost-saving implications both within Add-Aspirin and for future trials. 
 
Description Add-Aspirin interview for BBC World TV 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Professor Langley gave an interview for BBC World TV about the launch of the Add-Aspirin clinical trial. The launch was picked up by the news media internationally and prompted requests for further information, both from the general public and from other research groups.
Year(s) Of Engagement Activity 2015
 
Description Add-Aspirin interview for Today Programme 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Professor Langley gave a radio interview for the Today Programme about the launch of the Add-Aspirin clinical trial. The launch was picked up by the news media internationally and prompted requests for further information about the trial from both the general public and other research groups.
Year(s) Of Engagement Activity 2015
 
Description Add-Aspirin interview in The Observer 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Interview regarding the Add-Aspirin trial included in an article in The Observer
Year(s) Of Engagement Activity 2016
URL https://www.theguardian.com/science/2016/jun/12/anti-cancer-drugs-medicine-cabinet-repurposed-aspiri...
 
Description Add-Aspirin leaflets at the NCRN Clinical Studies Group trials meetings 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Leaflets about the Add-Aspirin trial were included in delegate packs for the NCRN urological and breast Clinical Studies Group trials meetings early in 2016, and some of the trials unit team attended the meetings. Attendees at the meetings included research teams from sites that were already participating in the trial and some that were going through the set-up process or interested in participating. Thus, it provided an opportunity to engage with these researchers and further raise awareness of the trial.
Year(s) Of Engagement Activity 2016
 
Description Add-Aspirin methodology seminar at ICR CTSU 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Invited to give a trials methodology seminar at the Institute of Cancer Research clinical trials unit covering novel aspects in the design and conduct of the Add-Aspirin trial. The talk prompted some interesting discussions and is expected to lead to future sharing of knowledge and experience between the two trials units.
Year(s) Of Engagement Activity 2016
 
Description Add-Aspirin oral presentation at ESMO world congress on Gastrointestinal Cancer Conference 2014 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact Oral presentation and poster presentation entitled "Are the Benefits of Aspirin in Colorectal Cancer Limited to PIK3CA Mutated Cancers?" at an international conference. The talk promoted discussion and raised awareness of the Add-Aspirin trial.


Promoted discussion
Year(s) Of Engagement Activity 2014
URL http://annonc.oxfordjournals.org/content/25/suppl_2/ii109.3.short
 
Description Add-Aspirin poster at BAUS meeting 2017 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Poster on Add-Aspirin trial prostate cohort presented at the British Association of Urological Surgeons annual meeting (June 2017)
Year(s) Of Engagement Activity 2017
 
Description Add-Aspirin poster at the American Society of Clinical Oncology (ASCO) annual meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Type Of Presentation poster presentation
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Poster presented at the largest oncology conference worldwide to raise awareness and promote interest in the Add-Aspirin trial: "Add-Aspirin Trial: A phase III, double blind, placebo-controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours".

Trial promotion and discussion with international experts
Year(s) Of Engagement Activity 2014
URL http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS1617
 
Description Add-Aspirin posters at BAUS meetings 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Posters on the Add-Aspirin clinical trial were displayed at the British Association of Urological Surgeons annual scientific meeting and annual meeting in June and November 2015. The posters were designed to raise awareness of the trial amongst this community who will play a key role in recruitment to the prostate cancer cohort of the trial.
Year(s) Of Engagement Activity 2015
 
Description Add-Aspirin presentation at Thames Valley Cancer Research Network event 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Professor Langley gave a presentation about the Add-Aspirin trial at the Thames Valley Cancer Research Network away-day. This was an opportunity to engage with research teams at sites that might participate in the trial. Subsequently, a number of sites in this network have opened to recruit to the trial.
Year(s) Of Engagement Activity 2015
 
Description Add-Aspirin press releases for trial launch 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact A national press release, and a number of regional releases, were published to announce the launch of the Add-Aspirin clinical trial. The release was picked up by the news media internationally and prompted a number of requests for interviews from the media and requests for further information about the trial from both the general public and other research groups.
Year(s) Of Engagement Activity 2015
URL http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2015-10-22-worlds-largest-clinica...
 
Description Add-Aspirin trial launch meeting at NCRI conference Liverpool 2014 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Health professionals
Results and Impact Add-Aspirin trial launch meeting- Trial promotion and training for research nurses and doctors hoping to participate in the trial at their site.

Increased requests for further information from sites interested in participating in the trial.
Year(s) Of Engagement Activity 2014
 
Description Add-Aspirin trial training events for participating site teams 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Prior to opening the Add-Aspirin clinical trial, two training events were held (in London and in Edinburgh) which were designed to provide teams from participating sites information about the trial and guidance on running it at their site. Attendees included Research Nurses, Trial Co-ordinators, Pharmacists and Clinicians. Other similar training sessions were held via WebEx, reaching staff at more than 100 sites expecting to participate in the trial. Most attendees have subsequently completed the trial set-up process and opened their site to recruit to the trial.
Year(s) Of Engagement Activity 2015
 
Description Add-Aspirin website 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Study participants or study members
Results and Impact The Add-Aspirin clinical trial website has been designed to provide information and updates about the trial to study participants, research teams at participating trial sites, other research groups and the general public.
Year(s) Of Engagement Activity 2015
URL http://www.addaspirintrial.org
 
Description Aspirin and cancer - ESMO 2017 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Ruth Langley presented a talk entitled "Aspirin for prevention and adjuvant treatment of cancer" at the European Society for Medical Oncology (ESMO) annual congress in September 2017, Madrid, Spain.
Year(s) Of Engagement Activity 2017
 
Description Aspirin trialists collaborative group meeting (Vienna, 2015) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This was the initial meeting of a new collaborative group of international researchers leading trials investigating the effects of aspirin in colorectal cancer. The formation of this group is expected to lead to future formal collaborations - for example, on meta-analyses of trial data.
Year(s) Of Engagement Activity 2015
 
Description Briefing paper on QUARTZ results 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact We produced a briefing paper about the QUARTZ trial results, aimed at policymakers and practitioners.
Year(s) Of Engagement Activity 2016
URL http://www.ctu.mrc.ac.uk/12602/13009/quartz_briefing_paper_020916
 
Description EURAMOS good responders lay summary 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Participants in your research and patient groups
Results and Impact Lay summary of trial results (First results of the EURAMOS-1: Information for trial participants and families) was prepared and made available via the trial website and sent to investigators to give to participants.

Unknown
Year(s) Of Engagement Activity 2013
URL http://www.euramos.org
 
Description EURAMOS-1 Overview at NCRI 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentation of EURAMOS-1 design, results (particularly Poor Response randomisation) and implications at UK National Cancer Research Institute 2015 conference by Jeremy Whelan (UCL, London). This was an invited talk to a session on clinical trials in rare cancers.
Year(s) Of Engagement Activity 2015
 
Description EURAMOS-1 Poor Responders at CTOS 2014 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The results of the Poor Response randomisation of the EURAMOS-1 were presented for the first time at the Connective Tissue Oncology Society meeting 2015 in Berlin, Germany, by Neyssa Marina (Stanford, CA, USA), one of the lead clinicians for the trial. The analysis were done and the slides prepared by MRC CTU at UCL.
This will change practice despite not finding in favour of the research arm. A paper was submitted for publication late in 2015.
Year(s) Of Engagement Activity 2014
 
Description EURAMOS-1 surgery data: oral presentation at CTOS 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Data on surgery in EURAMOS-1 trial were presented orally at the Connective Tissue Oncology Society meeting 2015 in Salt Lake City, UT, USA. The presentation was given by surgeon Rob Grimer. The analyses were led by, and slides prepared by, MRC CTU at UCL.
Year(s) Of Engagement Activity 2015
 
Description EURAMOS-1 surgery data: oral presentation at ISOLS 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Data on surgery in EURAMOS-1 trial were presented orally at the International Society Of Limb Salvage meeting 2015 in Florida, USA. The presentation was given by surgeon Rob Grimer. The analyses were led by, and slides prepared by, MRC CTU at UCL.
Year(s) Of Engagement Activity 2015
 
Description Event to receive donation from Friends of CRUK on behalf of CRUK 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Attendance at a publicised event to accept a donation of £45,000 on behalf of Cancer Research UK from the Putney, Barnes, Sheen and Kew Group of Friends of Cancer Research UK. This donation was a result of the South West London Christmas Fair fundraising event.
Year(s) Of Engagement Activity 2017
 
Description Films about PROMIS results 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Prostate Cancer UK, in partnership with the MRC Clinical Trials Unit at UCL, has released a series of short films on how multi-parametric MRI scans can improve prostate cancer diagnosis. These films are based on the results of the PROMIS study. Two of the films are aimed at clinicians, giving a summary of the study and its results, and how mpMRI can be used a triage for TRUS biopsy. The third film is aimed at patients, exploring the PROMIS results and what they mean for prostate cancer diagnosis.
Year(s) Of Engagement Activity 2017
URL https://www.youtube.com/playlist?list=PL1E-4A23O0jxZK4hJcghd0OgDnh4Z03VH
 
Description ICON8 ASCO 2014 Poster 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Poster presenting an update to the ICON8 trial at ASCO 2014
Year(s) Of Engagement Activity 2014
 
Description ICON8 ENGOT Frankfurt 2014 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Trial update presentation
Year(s) Of Engagement Activity 2014
 
Description ICON8 ENGOT Liverpool 2013 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Trial update presentation
Year(s) Of Engagement Activity 2013
 
Description ICON8 ENGOT Madrid 2014 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Trial update presentation
Year(s) Of Engagement Activity 2014
 
Description ICON8 ENGOT Nice 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Trial update presentation
Year(s) Of Engagement Activity 2015
 
Description ICON8 ENGOT Vienna 2012 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Trial Update Presentation
Year(s) Of Engagement Activity 2012
 
Description ICON8 ESGO Stage 1A results 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact ICON8 Stage 1A results
Year(s) Of Engagement Activity 2013,2014
 
Description ICON8 GCIG Chicago 2014 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Trial update presentation
Year(s) Of Engagement Activity 2006,2014
 
Description ICON8 GCIG Chicago 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Trial update presentation
Year(s) Of Engagement Activity 2015
 
Description ICON8 GCIG London 2013 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Trial update presentation
Year(s) Of Engagement Activity 2013
 
Description ICON8 GCIG Melbourne 2014 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Trial update presentation
Year(s) Of Engagement Activity 2014
 
Description ICON8 GCIG Stage 1A results 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact ICON8 GCIG Stage 1A results
Year(s) Of Engagement Activity 2013
 
Description ICON8 GCIG Tokyo 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Trial update
Year(s) Of Engagement Activity 2015
 
Description ICON8 Launch Meeting 2012 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Trial Launch Meeting
Year(s) Of Engagement Activity 2012
 
Description ICON8 NCRI Poster 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Poster: Current delays in setting-up investigator-driven randomised controlled trials: the MRC ICON8 experience
Year(s) Of Engagement Activity 2012
 
Description ICON8 NCRI Stage 1A results 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact ICON8 Stage 1A results
Year(s) Of Engagement Activity 2013
 
Description ICON8B Feedback Session 2014 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Feedback meeting with patient representatives, research nurses and data managers to gain feedback on ICON8B patient documents, trial protocol and CRFs
Year(s) Of Engagement Activity 2014
 
Description ICON8B Launch Meeting Glasgow 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Trial launch meeting and training presentation
Year(s) Of Engagement Activity 2015
 
Description ICON8B Launch Meeting London 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact ICON8B Trial Launch meeting and training presentation
Year(s) Of Engagement Activity 2015
 
Description MRC CTU at UCL joint urological trials regional meetings 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Four regional meetings were held in London, Bristol, Liverpool and Glasgow, with presentations from urological trials being conducted with the unit including PATCH, SORCE, RAMPART, STAMPEDE, RADICALS, Add-Aspirin, TRISST and PROMIS. As well as staff from participating sites, there were also patient representatives from the trials, and staff from Cancer Research UK, Prostate Cancer UK, and NIHR Clinical Research Network.
Year(s) Of Engagement Activity 2016
 
Description MRC Festival Symposium on Communicating Trial Results 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact The MRC Festival Symposium on Communicating Trial Results aimed to share examples of good practice, challenges and solutions around communicating the results of clinical trials, and to foster future collaboration. The MRC Clinical Trials Unit at UCL hosted the symposium, in partnership with the Association of Medical Research Charities.

With presentations, workshops, and lively discussion, attendees discussed the best ways to communicate the results of clinical trials to trial participants, patients, the clinical community and policymakers.

There were presentations and sessions with input from the Health Research Authority, Prostate Cancer UK, i-Base, the NCRI Consumer Forum, the MS Society and members of the MRC Clinical Trials Unit at UCL.
Year(s) Of Engagement Activity 2018
URL https://www.ctu.mrc.ac.uk/news/news-stories/2018/june/mrc-festival-2018-symposium-on-communicating-t...
 
Description NCRI London 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Trial update presentation
Year(s) Of Engagement Activity 2015
 
Description OE05 presentation at ASCO 2015 (Chicago) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact First presentation of OE05 trial results at ASCO conference in Chicago, US. Talk generated lots of discussion about the agents involved and the implications for future treatment.
Year(s) Of Engagement Activity 2015
URL http://meetinglibrary.asco.org/content/149773-156
 
Description OE05 presentation at ESMO 2015 (Vienna) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Further presentation of the OE05 trial results at the European Cancer Congress in Vienna. Lots of discussion regarding the impact of the results on future treatment.
Year(s) Of Engagement Activity 2015
URL http://www.ecco-org.eu/Vienna2015
 
Description Oral presentation on Add-Aspirin at BSG conference 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact An oral presentation on preliminary data from the run-in phase of Add-Aspirin presented at the British Society of Gastroenterology - Welsh Association of Gastroenterology & Endoscopy meeting (March 2018)
Year(s) Of Engagement Activity 2018
 
Description Ovarian CSG Meeting Dec 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Trial Update presentation
Year(s) Of Engagement Activity 2015
 
Description Overview of EURAMOS-1 trial at BSG 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentation by Matt Sydes at the British Sarcoma Group 2015 national conference in Nottingham 2015. The presentation gave an overview of the whole of the EURAMOS-1 trial to the appropriate clinical audience. This is the main national sarcoma conference for the UK.
Year(s) Of Engagement Activity 2015
 
Description PATCH presentation at a monthly Prostate Cancer UK meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact A brief presentation about the PATCH trials was given followed by questions from the attendees at the meeting, who comprised of communication officers and nurses who take phone calls from patients for Prostrate Cancer UK. The main aims were to inform the group about the study, and to discuss potential ways we can engage with them to help disseminate relevant information to patients and other healthcare professionals.
Year(s) Of Engagement Activity 2016
 
Description PATCH trial information stall at the NCRI Urological CSGs Trials Meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Stall showing information on the PATCH trial, including publications, for attendees at the meeting.
Year(s) Of Engagement Activity 2016
 
Description PPI workshop (Add-Aspirin) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Involvement in teaching on a workshop about Patient and Public Involvement (PPI) in trials - sharing experiences from the Add-Aspirin trial. The workshop was primarily focused at people working in clinical trials. Participants were engaged and took away new ideas about how best to go about involving patients and the public in their research.
Year(s) Of Engagement Activity 2016
 
Description PROMIS Twitter Q&A 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact We held a Twitter Q&A on the PROMIS trial results #prostateMRI
Year(s) Of Engagement Activity 2017
URL http://www.ctu.mrc.ac.uk/news/2017/prostateMRI_QandA_storify_16022017
 
Description PROMIS briefing paper 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Briefing paper summarising the results and implications of the PROMIS study.
Year(s) Of Engagement Activity 2017
URL http://www.ctu.mrc.ac.uk/12602/13009/PROMIS_briefing_paper_jan_2017
 
Description Poster at NCRI 2017 conference on co-enrolment in Add-Aspirin trial 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Scientific poster on co-enrolment within the Add-Aspirin clinical trial - presented at the annual National Cancer Research Institute (NCRI) conference 2017
Year(s) Of Engagement Activity 2017
 
Description Press release for Add-Aspirin launch in Republic of Ireland 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Press release to launch recruitment to the Add-Aspirin clinical trial in the Republic of Ireland, which was reported across a number of media outlets nationally.
Year(s) Of Engagement Activity 2018
 
Description Prostate Cancer Patients roadshows 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Events across a number of research centres in the UK were organised by Cancer Research UK and the MRC Clinical Trials Unit (CTU) at UCL for men affected by prostate cancer and their families, and there were presentations/stands from some of the trials within the CTU including STAMPEDE and PATCH.
Year(s) Of Engagement Activity 2016
 
Description Prostate cancer trials poster presentation at the British Association of Urological Surgeons Autumn Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact A poster was presented summarising the prostate cancer trials coordinated at the MRC Clinical Trials Unit at UCL which are currently recruiting patients (PATCH, STAMPEDE, RADICALS, and Add-Aspirin). This was intended to help clarify the patients eligible for each trials, in terms of clinical pathways.
Year(s) Of Engagement Activity 2015
 
Description Quartz presentation NCRI 2015 (Liverpool) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentation of Quartz results at NCRI conference, to a largely UK audience.
Year(s) Of Engagement Activity 2015
URL http://conference.ncri.org.uk/wp-content/uploads/2015/11/NCRI-2015-Programme.pdf
 
Description Quartz presentation at ASCO 2015 (Chicago) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Main results of Quartz trial presented for the first time at ASCO conference. Involved a large audience, and generated lots of questions/discussion.
Year(s) Of Engagement Activity 2015
URL http://meetinglibrary.asco.org/content/149588-156
 
Description Quartz presentation at BTOG 2016 (Dublin) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited presentation at BTOG conference in Dublin, discussing the impact of the Quartz results on the general treatment of patients with brain metastases.
Year(s) Of Engagement Activity 2016
URL http://www.btog.org/editorimages/BTOG%202016%20Programme%20FINAL4.pdf
 
Description Quartz presentation at World Lung 2015 (Denver) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Further presentation of Quartz results at World Lung conference in Denver, US. Several questions raised afterwards.
Year(s) Of Engagement Activity 2015
URL https://www.iaslc.org/events/16th-world-conference-lung-cancer
 
Description Quartz presentations at Best of ASCO 2015 (Boston, Chicago and San Francisco) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Following the trial presentation at the main ASCO meeting, it was selected to be presented at the "Best of" ASCO meetings held in the US. Presentations weren't made by members of the trial team.
Year(s) Of Engagement Activity 2015
URL http://boa.asco.org/
 
Description TRICON8B Launch NCRI Glasgow 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact TRICON8B Launch NCRI Glasgow 2016
Year(s) Of Engagement Activity 2016
 
Description TRISST patient newsletter 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Study participants or study members
Results and Impact TRISST trial newsletters, containing the latest study news, were distributed to all trial participants via participating centres.
Year(s) Of Engagement Activity 2015
 
Description Trial Management Group Meeting- Patient and Public Involvement 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact A patient representative is invited to attend every ICON8/ICON8B Trial Management Group meeting (held 3 monthly). We have 3 patient representatives that are members of our gynaecological oncology Trial Management Groups.
Year(s) Of Engagement Activity 2014,2015,2016,2017